v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
REVENUES        
Total revenues $ 0 $ 130 $ 0 $ 130
OPERATING EXPENSES        
Research and development 3,816 3,152 7,015 6,103
General and administrative 2,968 2,543 6,049 5,450
Total operating expenses 6,784 5,695 13,064 11,553
Loss from operations (6,784) (5,565) (13,064) (11,423)
OTHER INCOME (EXPENSE), NET        
Interest expense (203) (9) (392) (9)
Change in fair value of warrants 50 (956) 154 33
Change in fair value of tranche liability 347 0 1,377 0
Loss on extinguishment of financial commitment assets and contingent warrants, net 0 0 (1,616) 0
Other income, net 234 68 287 115
Total other income (expense), net 428 (897) (190) 139
NET LOSS (6,356) (6,462) (13,254) (11,284)
Less: Net loss attributable to noncontrolling interest 0 (14) 0 (23)
NET LOSS ATTRIBUTABLE TO SERINA THERAPEUTICS, INC. (6,356) (6,448) (13,254) (11,261)
NET LOSS ATTRIBUTABLE TO SERINA COMMON STOCKHOLDERS $ (8,932) $ (6,565) $ (15,867) $ (11,378)
NET LOSS ATTRIBUTABLE TO SERINA COMMON STOCKHOLDER, BASIC (in usd per share) $ (0.55) $ (0.66) $ (1.11) $ (1.15)
NET LOSS ATTRIBUTABLE TO SERINA COMMON STOCKHOLDER, DILUTED (in usd per share) $ (0.55) $ (0.66) $ (1.11) $ (1.15)
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING, BASIC (in shares) 16,385 10,004 14,232 9,883
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING, DILUTED (in shares) 16,385 10,004 14,232 9,883
Grant revenues        
REVENUES        
Total revenues $ 0 $ 130 $ 0 $ 130